Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECT: Aspirin vs LMWH for Thrombosis Prevention in Hip Fractures
NCT06937372Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin in venous thromboembolism (VTE) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: 90-Day Symptomatic Venous Thromboembolism (VTE) and All-Cause Mortality. Started Jul 2026; status: recruiting.
02
Drugs
aspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06937372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937372.